



Laboratory Bulletin

Leaders in Laboratory Medicine	Lead	ders in	Laborator	y Medicine
--------------------------------	------	---------	-----------	------------

DATE:	29 August 2023
TO:	South Sector: Physicians, Nurses and Healthcare Providers, Laboratory Staff
FROM:	Clinical Biochemistry, South Sector, Alberta Precision Laboratories (APL) & DynaLIFE Medical Labs
RE:	Anti-Endomysial Antibody (EMA) Testing: Discontinuation of Automated Reflex

PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

Key Message

- The historical automated reflex to Anti-Endomysial Antibody (EMA) testing on positive Tissue
 Transglutaminase-IgA (TTG-IgA) has been discontinued for all patients except for pediatric samples
 with TTG-IgA ≥ 150 kIU/L that are tested in Calgary.
- TTG-IgA is now recognized as the gold standard for diagnosing patients with Celiac Disease.
 - o Only in select circumstances does anti-EMA add diagnostic value.
- Anti-EMA remains available to order in patients with equivocal or confounding TTG-IgA results, with approval by the Clinical Biochemist.
- The reporting comments for TTG-IgA and anti-EMA testing will be updated appropriately.

How this will impact you

- Anti-TTG and anti-EMA results are often used together for diagnosis and monitoring of Celiac Disease. However, the relatively poor sensitivity of anti-EMA testing limits its clinical value.
- In adults, a positive TTG-IgA result should be followed by a consult with gastroenterology for biopsy.
- To limit the need for biopsy in children, the anti-EMA test may be used as a confirmation of the TTG-IgA result.
- This change is for TTG-IgA and anti-EMA testing performed at DynaLIFE and APL facilities in Calgary.
 - o The algorithm for these analytes tested in Edmonton will remain unchanged.

Effective

August 31, 2023

Inquiries and feedback may be directed to

- Dennis Orton, Clinical Biochemist, APL Calgary, 403-770-3219 | <u>Dennis Orton@aplabs.ca</u>
- Jessica Gifford, Clinical Biochemist, DynaLIFE Medical Labs, 403-770-3779 | Jessica Gifford@ahs.ca

This bulletin has been reviewed and approved by

- Dr. Allison Venner, Associate Section Chief, Clinical Biochemistry, South Sector, APL
- Dr. Paul Klonowski, Associate Medical Director, South Sector, APL
- Dr. Jessica Gifford, Clinical Chemistry Lead, DynaLIFE Medical Labs
- Dr. Erene Farag, Provincial Medical Director, DynaLIFE Medical Labs